United States - English - NLM (National Library of Medicine)

bryant ranch prepack - clomipramine hydrochloride (unii: 2lxw0l6gwj) (clomipramine - unii:nuv44l116d) - clomipramine hydrochloride capsules usp is indicated for the treatment of obsessions and compulsions in patients with obsessive-compulsive disorder (ocd). the obsessions or compulsions must cause marked distress, be time-consuming, or significantly interfere with social or occupational functioning, in order to meet the dsm-iii-r (circa 1989) diagnosis of ocd. obsessions are recurrent, persistent ideas, thoughts, images, or impulses that are ego-dystonic. compulsions are repetitive, purposeful, and intentional behaviors performed in response to an obsession or in a stereotyped fashion, and are recognized by the person as excessive or unreasonable. the effectiveness of clomipramine hydrochloride capsules for the treatment of ocd was demonstrated in multicenter, placebo-controlled, parallel-group studies, including two 10-week studies in adults and one 8-week study in children and adolescents 10 to 17 years of age. patients in all studies had moderate-to-severe ocd (dsm-iii), with mean baseline ratings on the ya

United States - English - NLM (National Library of Medicine)

attix pharmaceuticals inc - clomipramine hydrochloride (unii: 2lxw0l6gwj) (clomipramine - unii:nuv44l116d) -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - clomipramine hydrochloride, quantity: 25 mg - tablet, film coated - excipient ingredients: purified talc; maize starch; lactose monohydrate; sodium starch glycollate; magnesium stearate; povidone; titanium dioxide; hypromellose; macrogol 400 - for the treatment o f major depression; obsessive-compulsive disorders and phobias in adults; and cataplexy associated with narcolepsy.

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals ny llc - clomipramine hydrochloride (unii: 2lxw0l6gwj) (clomipramine - unii:nuv44l116d) - clomipramine hydrochloride capsules are indicated for the treatment of obsessions and compulsions in patients with obsessive-compulsive disorder (ocd). the obsessions or compulsions must cause marked distress, be time-consuming, or significantly interfere with social or occupational functioning, in order to meet the dsm-iii-r (circa 1989) diagnosis of ocd. obsessions are recurrent, persistent ideas, thoughts, images, or impulses that are ego-dystonic. compulsions are repetitive, purposeful, and intentional behaviors performed in response to an obsession or in a stereotyped fashion, and are recognized by the person as excessive or unreasonable. the effectiveness of clomipramine hydrochloride capsules for the treatment of ocd was demonstrated in multicenter, placebo-controlled, parallel-group studies, including two 10-week studies in adults and one 8-week study in children and adolescents 10 to 17 years of age. patients in all studies had moderate-to-severe ocd (dsm-iii), with mean baseline ratings on the yale-brown obsessive compulsive scale (ybocs) ranging from 26 to 28 and a mean baseline rating of 10 on the nimh clinical global obsessive compulsive scale (nimh-oc). patients taking cmi experienced a mean reduction of approximately 10 on the ybocs, representing an average improvement on this scale of 35% to 42% among adults and 37% among children and adolescents. cmi-treated patients experienced a 3.5 unit decrement on the nimh-oc. patients on placebo showed no important clinical response on either scale. the maximum dose was 250 mg/day for most adults and 3 mg/kg/day (up to 200 mg) for all children and adolescents. the effectiveness of clomipramine hydrochloride capsules for long-term use (i.e. for more than 10 weeks) has not been systematically evaluated in placebo-controlled trials. the physician who elects to use clomipramine hydrochloride capsules for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see dosage and administration ). clomipramine hydrochloride capsules are contraindicated in patients with a history of hypersensitivity to clomipramine hydrochloride or other tricyclic antidepressants. monoamine oxidase inhibitors (maois) the use of maois intended to treat psychiatric disorders with clomipramine hydrochloride or within 14 days of stopping treatment with clomipramine hydrochloride is contraindicated because of an increased risk of serotonin syndrome. the use of clomipramine hydrochloride within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated (see  warnings and dosage and administration ). starting clomipramine hydrochloride in a patient who is being treated with linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see  warnings and dosage and administration ). myocardial infarction clomipramine hydrochloride is contraindicated during the acute recovery period after a myocardial infarction. clomipramine hydrochloride has not been systematically studied in animals or humans for its potential for abuse, tolerance, or physical dependence. while a variety of withdrawal symptoms have been described in association with clomipramine hydrochloride discontinuation (see precautions, withdrawal symptoms ), there is no evidence for drug-seeking behavior, except for a single report of potential clomipramine hydrochloride abuse by a patient with a history of dependence on codeine, benzodiazepines, and multiple psychoactive drugs. the patient received clomipramine hydrochloride for depression and panic attacks and appeared to become dependent after hospital discharge. despite the lack of evidence suggesting an abuse liability for clomipramine hydrochloride in foreign marketing, it is not possible to predict the extent to which clomipramine hydrochloride might be misused or abused once marketed in the u.s. consequently, physicians should carefully evaluate patients for a history of drug abuse and follow such patients closely.

United States - English - NLM (National Library of Medicine)

novartis animal health us, inc. - clomipramine hydrochloride (unii: 2lxw0l6gwj) (clomipramine - unii:nuv44l116d) - clomipramine hydrochloride 5 mg

Malta - English - Medicines Authority

remedica limited limassol industrial estate, aharnon street, 3056 limassol, cyprus - clomipramine hydrochloride - film-coated tablet - clomipramine hydrochloride 10 mg - psychoanaleptics

Malta - English - Medicines Authority

remedica limited limassol industrial estate, aharnon street, 3056 limassol, cyprus - clomipramine hydrochloride - film-coated tablet - clomipramine hydrochloride 25 mg - psychoanaleptics

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - clomipramine hydrochloride, quantity: 25 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; colloidal anhydrous silica; hypromellose; macrogol 3350; titanium dioxide; iron oxide yellow; carnauba wax - major depression. obsessive-compulsive disorders and phobias in adults. cataplexy associated with narcolepsy.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

mavlab pty. ltd. - clomipramine hydrochloride - unknown - clomipramine hydrochloride azepine active 0.0 - active constituent

United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - clomipramine hydrochloride (unii: 2lxw0l6gwj) (clomipramine - unii:nuv44l116d) - clomipramine hydrochloride 495 g in 1 g